Romania

Show information for:

Information and guides

BackSavedSign in

Support / Info

Clinical trials for colorectal cancer in Romania

Which studies are listed as recruiting, where the centres are, and how to contact the team. Record source: ClinicalTrials.gov.

← All cancer types

How to read this list

Each card is a study listed as recruiting with a recruiting centre in Romania. Open the sections in the card to see the participant overview, study groups, calendar and all published local centres and contacts. The study team confirms eligibility and availability; the original registry record remains available for the complete protocol information.

Trials recruiting now

Every title below has been rewritten in plain language by our editorial team, with the original underneath.

Trials testing a treatment · 5 studies

Something new is being tried here: a medicine, a regimen or a procedure. If you join, you receive either the treatment under study or the standard one, and the team follows you closely.

NCT06252649Phase 3Listed as recruiting

Untreated metastatic colorectal cancer with a KRAS G12C mutation: sotorasib and panitumumab added to chemotherapy

The aim of this study is to compare progression free survival (PFS) in treatment-naïve participants with KRAS p.G12C mutated metastatic colorectal cancer (mCRC) receiving sotorasib, panitumumab and FOLFIRI vs FOLFIRI with or without bevacizumab-awwb.

Minimum age: 18 years

Centres in: București · Cluj-Napoca · Craiova · and 3 more cities

See all centres (7)

These centres appear in the record of a recruiting study. Confirm availability with the team before travelling. One centre may have several teams with different contacts.

Central study contact

To find the team and exact institution in your chosen city, quote study NCT06252649. This contact may be in another country; ask which language you can use.

Amgen Call Center

866-572-6436 (dialling format unconfirmed)

medinfo@amgen.com

Source: study registry

We could not read the directory's general contacts right now. Contacts published in the registry are shown in this card.

București

Cluj-Napoca

Craiova

Iași

Ploiești

Timișoara

Who can take part

Untreated metastatic colorectal cancer with a KRAS G12C mutation: sotorasib and panitumumab added to chemotherapy

The aim of this study is to compare progression free survival (PFS) in treatment-naïve participants with KRAS p.G12C mutated metastatic colorectal cancer (mCRC) receiving sotorasib, panitumumab and FOLFIRI vs FOLFIRI with or without bevacizumab-awwb.

Minimum age:
18 years
Maximum age:
Not specified in the record consulted
Participant sex, as recorded in the registry:
All sexes

This is an overview, not confirmation of eligibility. The study team reviews your records, the inclusion and exclusion criteria and the other protocol requirements.

Criteria published in the registry — English original

Inclusion Criteria: * Pathologically documented metastatic colorectal adenocarcinoma with KRAS p.G12C mutation by a locally validated assay. * Central laboratory detection of KRAS p.G12C mutation. * Measurable metastatic disease per RECIST v1.1 criteria. * Eastern Cooperative Oncology Group (ECOG) Performance Status of ≤ 1. * Adequate organ function. Exclusion Criteria: * Active, untreated brain metastases. * Leptomeningeal disease * Previous treatment with a KRAS p.G12C inhibitor * History of interstitial pneumonitis or pulmonary fibrosis or evidence of interstitial pneumonitis or pulmonary fibrosis on baseline CT scan

What taking part involves

Participants are randomly assigned to the study groups.

These source names are associated with each group and may include alternatives or different stages. They do not imply that all are given simultaneously. The team explains the regimen, doses and schedule.

  • Group 1 · Studied intervention

    FOLFIRI Regimen · Sotorasib · Panitumumab

  • Group 2 · Active treatment comparison

    FOLFIRI Regimen · Bevacizumab-awwb

Start of the whole study
17 July 2024
Completion of the whole study
25 April 2032 (estimated)

These are global study dates, not an individual's participation duration or an enrolment deadline.

Confirm participation duration, visit frequency and possible admissions with the centre team; they cannot be inferred from global study dates.

Ask the study team before travelling:

  • whether places are available at the chosen centre and how the first assessment is arranged
  • how often you need to attend the centre and whether a hospital stay is necessary
  • whether travel or accommodation costs are covered and under what conditions
  • which documents you need to prepare and whether a family member or carer can accompany you
Original registry title

Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation

Updated in the registry: 3 September 2026

Data consulted: 19 November 2026

See the official record ↗

If the official record does not open, you can still read the information and contacts in this card. The ClinicalTrials.gov record is in English.

NCT06750094Phase 3Listed as recruiting

Colorectal cancer without KRAS, NRAS and BRAF mutations, after chemotherapy: amivantamab compared with cetuximab or bevacizumab

The purpose of this study is to compare how long the participants are disease-free (progression-free survival) and and the length of time until a participant dies (overall survival), when treated with amivantamab and chemotherapy with 5-fluorouracil, leucovorin calcium (folinic acid) or levoleucovorin, and irinotecan hydrochloride (FOLFIRI) versus either cetuximab or bevacizumab and FOLFIRI given to participants with Kirsten rat sarcoma viral oncogene/ neuroblastoma RAS viral oncogene homolog (KRAS/ NRAS) and v-raf murine sarcoma viral oncogene homolog B (BRAF) wild-type recurrent, unresectable or metastatic colorectal cancer who have previously received chemotherapy.

Minimum age: 18 years

Centres in: Brașov · București · Cluj-Napoca · and 3 more cities

See all centres (6)

These centres appear in the record of a recruiting study. Confirm availability with the team before travelling. One centre may have several teams with different contacts.

Central study contact

To find the team and exact institution in your chosen city, quote study NCT06750094. This contact may be in another country; ask which language you can use.

Study Contact

844-434-4210 (dialling format unconfirmed)

Participate-In-This-Study1@its.jnj.com

Source: study registry

We could not read the directory's general contacts right now. Contacts published in the registry are shown in this card.

Brașov

București

Cluj-Napoca

Craiova

Iași

Oradea

Who can take part

Colorectal cancer without KRAS, NRAS and BRAF mutations, after chemotherapy: amivantamab compared with cetuximab or bevacizumab

The purpose of this study is to compare how long the participants are disease-free (progression-free survival) and and the length of time until a participant dies (overall survival), when treated with amivantamab and chemotherapy with 5-fluorouracil, leucovorin calcium (folinic acid) or levoleucovorin, and irinotecan hydrochloride (FOLFIRI) versus either cetuximab or bevacizumab and FOLFIRI given to participants with Kirsten rat sarcoma viral oncogene/ neuroblastoma RAS viral oncogene homolog (KRAS/ NRAS) and v-raf murine sarcoma viral oncogene homolog B (BRAF) wild-type recurrent, unresectable or metastatic colorectal cancer who have previously received chemotherapy.

Minimum age:
18 years
Maximum age:
Not specified in the record consulted
Participant sex, as recorded in the registry:
All sexes

This is an overview, not confirmation of eligibility. The study team reviews your records, the inclusion and exclusion criteria and the other protocol requirements.

Criteria published in the registry — English original

Inclusion Criteria: * Have histologically or cytologically confirmed adenocarcinoma of the colon or rectum. Participants must have recurrent, unresectable or metastatic disease * Determined to have kirsten rat sarcoma viral oncogene/neuroblastoma RAS viral oncogene homolog (KRAS/NRAS), G12, G13 and v-raf murine sarcoma viral oncogene homolog B (BRAF) V600X (X represents any single amino acid change from the original amino acid) wild type status by local and/or central next-generation sequencing (NGS) testing * Must agree to the submission of fresh or archival tumor tissue post progression from the most recent therapy, if clinically feasible * Have measurable disease according to response evaluation criteria in solid tumors (RECIST) version (v) 1.1 * Have an eastern cooperative oncology group (ECOG) performance status (PS) of 0 or 1 * Participant must have received 1 line of systemic therapy (fluoropyrimidine-based and oxaliplatin-based) for metastatic colorectal cancer (mCRC), with documented radiographic disease progression on or after this line of therapy. Participants can receive anti-VEGF as prior line of therapy Exclusion Criteria: * Has medical history of (noninfectious) interstitial lung disease (ILD) /pneumonitis/pulmonary fibrosis or has current ILD/pneumonitis/pulmonary fibrosis, or where suspected ILD/pneumonitis/pulmonary fibrosis cannot be ruled out by imaging at screening * Has known allergies, hypersensitivity, or intolerance to excipients of any of the following: amivantamab, cetuximab or bevacizumab or any component of FOLFIRI * Has a prior or concurrent second malignancy other than the disease under study or one whose natural history or treatment is likely to interfere with any study endpoints of safety or the efficacy of the study treatment(s) * Participant with known mismatch repair deficiency (dMMR)/ high microsatellite instability (MSI-H) status who has not received immunotherapy treatments * Participant with known human epidermal growth factor receptor 2 (HER2)- positive/amplified tumor * Has prior exposure to irinotecan, any agents that target epidermal growth factor receptor (EGFR) or mesenchymal epithelial transition (MET)

What taking part involves

Participants are randomly assigned to the study groups.

These source names are associated with each group and may include alternatives or different stages. They do not imply that all are given simultaneously. The team explains the regimen, doses and schedule.

  • Group 1 · Studied intervention

    Amivantamab · 5-fluorouracil · Leucovorin calcium/Levoleucovorin · Irinotecan

  • Group 2 · Active treatment comparison

    Cetuximab · Bevacizumab · 5-fluorouracil · Leucovorin calcium/Levoleucovorin · Irinotecan

Start of the whole study
12 December 2024
Completion of the whole study
13 April 2029 (estimated)

These are global study dates, not an individual's participation duration or an enrolment deadline.

Confirm participation duration, visit frequency and possible admissions with the centre team; they cannot be inferred from global study dates.

Ask the study team before travelling:

  • whether places are available at the chosen centre and how the first assessment is arranged
  • how often you need to attend the centre and whether a hospital stay is necessary
  • whether travel or accommodation costs are covered and under what conditions
  • which documents you need to prepare and whether a family member or carer can accompany you
Original registry title

A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy

Updated in the registry: 3 November 2026

Data consulted: 19 November 2026

See the official record ↗

If the official record does not open, you can still read the information and contacts in this card. The ClinicalTrials.gov record is in English.

NCT07221357Phase 2Listed as recruiting

Untreated metastatic colorectal cancer: a new medicine with chemotherapy compared with bevacizumab with chemotherapy

The purpose of this study is to evaluate the safety and efficacy of pumitamig in combination with chemotherapy versus bevacizumab in combination with chemotherapy in participants with previously untreated, unresectable, or metastatic colorectal cancer

Minimum age: 18 years

Centres in: București · Cluj-Napoca · Craiova · and 2 more cities

See all centres (7)

These centres appear in the record of a recruiting study. Confirm availability with the team before travelling. One centre may have several teams with different contacts.

Central study contact

To find the team and exact institution in your chosen city, quote study NCT07221357. This contact may be in another country; ask which language you can use.

BMS Clinical Trials Contact Center www.BMSClinicalTrials.com

855-907-3286 (dialling format unconfirmed)

Clinical.Trials@bms.com

First line of the email MUST contain NCT # and Site #.

Source: study registry

We could not read the directory's general contacts right now. Contacts published in the registry are shown in this card.

București

  • Fundeni Clinical Institute

    Contact for this study

    Adina Croitoru

    Centre code in the registry: 0100

    +40 722 300 252

    Source: study registry

Cluj-Napoca

  • Institutul Regional de Gastroenterologie și Hepatologie Prof. Dr. Octavian Fodor

    Contact for this study

    Adrian Radu Vidra

    Centre code in the registry: 0282

    +40 724 251 696

    Source: study registry

  • Institutul Oncologic Cluj

    Contact for this study

    Tudor Ciuleanu

    Centre code in the registry: 0142

    +40 745 646 368

    Source: study registry

Craiova

  • Centrul de Oncologie "Sfântul Nectarie"

    Contact for this study

    Michael Schenker

    Centre code in the registry: 0189

    +40 727 774 974

    Source: study registry

Floresti/ Cluj

  • Amethyst Radiotherapy Center-Oncologie Medicala

    Contact for this study

    Andrei Ungureanu

    Centre code in the registry: 0139

    +40 742 206 212

    Source: study registry

Iași

  • S.C. Centrul de Oncologie Euroclinic S.R.L.

    Contact for this study

    Constantin Volovat

    Centre code in the registry: 0370

    +40 746 110 096

    Source: study registry

  • Institutul Regional de Oncologie

    Contact for this study

    Bogdan Gafton

    Centre code in the registry: 0143

    +40 766 307 558

    Source: study registry

Who can take part

Untreated metastatic colorectal cancer: a new medicine with chemotherapy compared with bevacizumab with chemotherapy

The purpose of this study is to evaluate the safety and efficacy of pumitamig in combination with chemotherapy versus bevacizumab in combination with chemotherapy in participants with previously untreated, unresectable, or metastatic colorectal cancer

Minimum age:
18 years
Maximum age:
Not specified in the record consulted
Participant sex, as recorded in the registry:
All sexes

This is an overview, not confirmation of eligibility. The study team reviews your records, the inclusion and exclusion criteria and the other protocol requirements.

Criteria published in the registry — English original

Inclusion Criteria * Participant must previously untreated, histologically confirmed recurrent or metastatic colorectal adenocarcinoma, not amenable to curative surgery. * Participant must have no known presence of mismatch repair deficient (dMMR) or microsatellite instability-high (MSI-H) colorectal cancer (CRC) per historical results (a validated test should be used). * Participant must have no known presence of the gene that encodes the protein B-Raf (BRAF) V600E mutation per local testing. * Participant must have measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. Exclusion Criteria * Participant must not have any untreated known central nervous system (CNS) metastases including brain, leptomeningeal and/or spinal cord compression. * Participant must not have any prior malignancy active within the previous 2 years, except for locally curable cancers that have been apparently cured and considered to be of low risk of recurrence. * Participant must not have significant cardiovascular disease, such as myocardial infarction, unstable angina, arterial thrombosis or cerebrovascular accident within 6 months prior to randomization, uncontrolled hypertension (≥ 160 systolic, and/or ≥ 100 diastolic mm Hg) despite optimal medical management, or congenital long QT syndrome. * Participant must not have prior systemic treatment with an anti-PD-1, anti-programmed death (ligand)-1 (PD-L1), anti-PD-L2, CD137 agonists, or anti-cytotoxic T-lymphocyte associated protein 4 (CTLA-4) antibody, or any other antibody or drug specifically targeting T cell co-stimulation or checkpoint pathways or chemotherapy. * Other protocol-defined Inclusion/Exclusion criteria apply.

What taking part involves

Participants are randomly assigned to the study groups.

These source names are associated with each group and may include alternatives or different stages. They do not imply that all are given simultaneously. The team explains the regimen, doses and schedule.

  • Group 1 · Studied intervention

    Pumitamig · FOLFOX · FOLFIRI

  • Group 2 · Studied intervention

    Pumitamig · FOLFOX · FOLFIRI

  • Group 3 · Group described in the registry

    FOLFOX · FOLFIRI · Bevacizumab

  • Group 4 · Studied intervention

    Pumitamig · FOLFOX · FOLFIRI · CAPOX

  • Group 5 · Group described in the registry

    FOLFOX · FOLFIRI · Bevacizumab · CAPOX

Start of the whole study
31 December 2025
Completion of the whole study
11 March 2034 (estimated)

These are global study dates, not an individual's participation duration or an enrolment deadline.

Confirm participation duration, visit frequency and possible admissions with the centre team; they cannot be inferred from global study dates.

Ask the study team before travelling:

  • whether places are available at the chosen centre and how the first assessment is arranged
  • how often you need to attend the centre and whether a hospital stay is necessary
  • whether travel or accommodation costs are covered and under what conditions
  • which documents you need to prepare and whether a family member or carer can accompany you
Original registry title

A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer

Updated in the registry: 23 October 2026

Data consulted: 19 November 2026

See the official record ↗

If the official record does not open, you can still read the information and contacts in this card. The ClinicalTrials.gov record is in English.

NCT06997497Phase 3Listed as recruiting

Colorectal cancer: calderasib added to targeted therapy and chemotherapy

Researchers are looking for other ways to treat locally advanced or metastatic colorectal cancer (mCRC) that is unresectable and has a gene mutation called KRAS G12C. Standard (or usual) treatments for this type of colorectal cancer may include mFOLFOX6 with or without bevacizumab. Researchers want to learn if adding calderasib (the study medicine) and cetuximab to mFOLFOX6 can treat locally advanced or mCRC with the KRAS G12C mutation. Calderasib and cetuximab are targeted therapies. The goals of this study are to learn: * About the safety of calderasib with cetuximab and mFOLFOX6 and if people tolerate the treatments * If people who receive calderasib with cetuximab and mFOLFOX6 live longer without mCRC growing or spreading compared to people who receive mFOLFOX6 with or without bevacizumab.

Minimum age: 18 years

Centres in: București · Cluj-Napoca · Craiova · and one more city

See all centres (5)

These centres appear in the record of a recruiting study. Confirm availability with the team before travelling. One centre may have several teams with different contacts.

Central study contact

To find the team and exact institution in your chosen city, quote study NCT06997497. This contact may be in another country; ask which language you can use.

Toll Free Number

1-888-577-8839 (dialling format unconfirmed)

Trialsites@msd.com

Source: study registry

We could not read the directory's general contacts right now. Contacts published in the registry are shown in this card.

București

  • Fundeni Clinical Institute-Medical Oncology

    Contact for this study

    Study Coordinator

    +40 21 275 0500

    Source: study registry

Cluj-Napoca

  • Institutul Oncologic Cluj

    Contact for this study

    Study Coordinator

    +40 264 598 362

    Source: study registry

  • SC Radiotherapy Center Cluj SRL-Oncologie Medicala

    Contact for this study

    Study Coordinator

    +40 21 9368

    Source: study registry

Craiova

  • Centrul de Oncologie Sfantul Nectarie-Medical

    Contact for this study

    Study Coordinator

    +40 731 604 432

    Source: study registry

Iași

  • Institutul Regional de Oncologie

    Contact for this study

    Study Coordinator

    +40 374 278 811

    Source: study registry

Who can take part

Colorectal cancer: calderasib added to targeted therapy and chemotherapy

Researchers are looking for other ways to treat locally advanced or metastatic colorectal cancer (mCRC) that is unresectable and has a gene mutation called KRAS G12C. Standard (or usual) treatments for this type of colorectal cancer may include mFOLFOX6 with or without bevacizumab. Researchers want to learn if adding calderasib (the study medicine) and cetuximab to mFOLFOX6 can treat locally advanced or mCRC with the KRAS G12C mutation. Calderasib and cetuximab are targeted therapies. The goals of this study are to learn: * About the safety of calderasib with cetuximab and mFOLFOX6 and if people tolerate the treatments * If people who receive calderasib with cetuximab and mFOLFOX6 live longer without mCRC growing or spreading compared to people who receive mFOLFOX6 with or without bevacizumab.

Minimum age:
18 years
Maximum age:
Not specified in the record consulted
Participant sex, as recorded in the registry:
All sexes

This is an overview, not confirmation of eligibility. The study team reviews your records, the inclusion and exclusion criteria and the other protocol requirements.

Criteria published in the registry — English original

Inclusion Criteria: The main inclusion criteria include but are not limited to the following: * Has a histologically confirmed diagnosis of locally advanced unresectable or metastatic (unresectable Stage III or Stage IV as defined by American Joint Committee on Cancer \[AJCC\] eighth edition) colorectal adenocarcinoma * Part 2 only: Has not received systemic anticancer therapy for locally advanced unresectable or metastatic colorectal cancer; an exception is permitted for 1-2 cycles of FOLFOX or 1 cycle of CAPOX as optional chemotherapy before or during the screening period * Demonstrates presence of a Kirsten rat sarcoma viral oncogene homolog G12C (KRAS G12C) mutation * Human immunodeficiency virus (HIV)-infected participants must have well controlled HIV on antiretroviral therapy (ART) * Participants who are Hepatitis B surface antigen (HBsAg) positive are eligible if they have received hepatitis B virus (HBV) antiviral therapy and have undetectable HBV viral load * Participants with history of hepatitis C virus (HCV) infection are eligible if HCV viral load is undetectable Exclusion Criteria: The main exclusion criteria include but are not limited to the following: * Has active inflammatory bowel disease requiring immunosuppressive medication or previous clear history of inflammatory bowel disease (eg, Crohn's disease, ulcerative colitis, chronic diarrhea) * Has uncontrolled, significant cardiovascular disease or cerebrovascular disease * Has known partial or complete dihydropyrimidine dehydrogenase (DPD) deficiency * HIV-infected participants with a history of Kaposi's sarcoma and/or Multicentric Castleman's Disease * Has received prior systemic anticancer therapy including investigational agents within 4 weeks before randomization, with the exception of the optional chemotherapy * Has 1 or more conditions that, in the opinion of the investigator, make the participant ineligible for treatment with bevacizumab * Has known additional malignancy that is progressing or has required active treatment within the past 3 years * Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis or leptomeningeal disease * Has active infection requiring systemic therapy * Has not adequately recovered from major surgery or have ongoing surgical complications * Has a history of (noninfectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/interstitial lung disease

What taking part involves

Participants are randomly assigned to the study groups.

These source names are associated with each group and may include alternatives or different stages. They do not imply that all are given simultaneously. The team explains the regimen, doses and schedule.

  • Group 1 · Studied intervention

    Calderasib · Oxaliplatin · Leucovorin/levofolinate calcium · 5-Fluorouracil · Cetuximab

  • Group 2 · Active treatment comparison

    Oxaliplatin · Leucovorin/levofolinate calcium · 5-Fluorouracil · Bevacizumab · Bevacizumab biosimilar

Start of the whole study
16 July 2025
Completion of the whole study
27 October 2030 (estimated)

These are global study dates, not an individual's participation duration or an enrolment deadline.

Confirm participation duration, visit frequency and possible admissions with the centre team; they cannot be inferred from global study dates.

Ask the study team before travelling:

  • whether places are available at the chosen centre and how the first assessment is arranged
  • how often you need to attend the centre and whether a hospital stay is necessary
  • whether travel or accommodation costs are covered and under what conditions
  • which documents you need to prepare and whether a family member or carer can accompany you
Original registry title

A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012)

Updated in the registry: 12 November 2026

Data consulted: 19 November 2026

See the official record ↗

If the official record does not open, you can still read the information and contacts in this card. The ClinicalTrials.gov record is in English.

NCT07881133No phaseListed as recruiting

Colorectal or gastric cancer surgery: biomarker monitoring and recovery after surgery

This study aims to evaluate whether monitoring perioperative inflammatory and metabolic biomarkers can help identify postoperative complications early in adult patients undergoing colorectal or gastric cancer surgery. The study is a randomized controlled trial conducted at Bucharest Emergency Clinical Hospital, Romania. Participants are assigned to either an intervention group receiving enhanced recovery care (ERAS) combined with perioperative biomarker monitoring or a control group receiving standard postoperative care. The biomarkers of interest include procalcitonin, lactate, and blood glucose. The study will examine their relationship with postoperative complications, particularly infections and anastomotic leakage. Participants will be followed for 30 days after surgery to assess postoperative complications, hospital length of stay, readmissions, and mortality. The findings may help improve postoperative monitoring and support earlier recognition of complications in patients undergoing cancer surgery.

Minimum age: 18 years

Centres in: București

See all centres (1)

These centres appear in the record of a recruiting study. Confirm availability with the team before travelling. One centre may have several teams with different contacts.

We could not read the directory's general contacts right now. Contacts published in the registry are shown in this card.

București

Who can take part

Colorectal or gastric cancer surgery: biomarker monitoring and recovery after surgery

This study aims to evaluate whether monitoring perioperative inflammatory and metabolic biomarkers can help identify postoperative complications early in adult patients undergoing colorectal or gastric cancer surgery. The study is a randomized controlled trial conducted at Bucharest Emergency Clinical Hospital, Romania. Participants are assigned to either an intervention group receiving enhanced recovery care (ERAS) combined with perioperative biomarker monitoring or a control group receiving standard postoperative care. The biomarkers of interest include procalcitonin, lactate, and blood glucose. The study will examine their relationship with postoperative complications, particularly infections and anastomotic leakage. Participants will be followed for 30 days after surgery to assess postoperative complications, hospital length of stay, readmissions, and mortality. The findings may help improve postoperative monitoring and support earlier recognition of complications in patients undergoing cancer surgery.

Minimum age:
18 years
Maximum age:
Not specified in the record consulted
Participant sex, as recorded in the registry:
All sexes

This is an overview, not confirmation of eligibility. The study team reviews your records, the inclusion and exclusion criteria and the other protocol requirements.

Criteria published in the registry — English original

Inclusion Criteria: * Adult patients aged 18 years or older. * Patients diagnosed with colorectal or gastric cancer. * Patients scheduled for elective abdominal oncologic surgery. * Patients classified as ASA physical status II-IV. * Patients who provide written informed consent to participate in the study. Exclusion Criteria: * Patients with known autoimmune or immunological diseases that may significantly influence inflammatory biomarker levels. * Patients diagnosed with inflammatory bowel disease (IBD). * Patients who refuse to participate or do not provide written informed consent.

What taking part involves

Participants are randomly assigned to the study groups.

These source names are associated with each group and may include alternatives or different stages. They do not imply that all are given simultaneously. The team explains the regimen, doses and schedule.

  • Group 1 · Studied intervention

    Perioperative Biomarker-Guided Monitoring

  • Group 2 · Without the studied intervention

    Not specified in the record consulted

Start of the whole study
25 February 2026
Completion of the whole study
January 2029 (estimated)

These are global study dates, not an individual's participation duration or an enrolment deadline.

Confirm participation duration, visit frequency and possible admissions with the centre team; they cannot be inferred from global study dates.

Ask the study team before travelling:

  • whether places are available at the chosen centre and how the first assessment is arranged
  • how often you need to attend the centre and whether a hospital stay is necessary
  • whether travel or accommodation costs are covered and under what conditions
  • which documents you need to prepare and whether a family member or carer can accompany you
Original registry title

Perioperative Biomarkers in Colorectal and Gastric Cancer Surgery

Updated in the registry: 19 October 2026

Data consulted: 19 November 2026

See the official record ↗

If the official record does not open, you can still read the information and contacts in this card. The ClinicalTrials.gov record is in English.

Observational studies · one study

You do NOT receive a new treatment here. You have your usual care, and researchers collect information about how it goes. Useful for people after you, but it does not change your own care.

NCT06033976Listed as recruiting

Observational registry: outcomes of endoscopic resection for digestive-tract tumours

This is a patient registry for all cases of pre-neoplastic or early neoplastic digestive tract lesions treated with curative intention by endoscopic submucosal dissection (ESD) technique.

Minimum age: 18 years

Centres in: București

See all centres (1)

These centres appear in the record of a recruiting study. Confirm availability with the team before travelling. One centre may have several teams with different contacts.

Central study contact

To find the team and exact institution in your chosen city, quote study NCT06033976. This contact may be in another country; ask which language you can use.

Ciocirlan L Mihai, Associate Professor

+40 722 322 625

mihai.ciocirlan@umfcd.ro

Source: study registry

We could not read the directory's general contacts right now. Contacts published in the registry are shown in this card.

București

Who can take part

Observational registry: outcomes of endoscopic resection for digestive-tract tumours

This is a patient registry for all cases of pre-neoplastic or early neoplastic digestive tract lesions treated with curative intention by endoscopic submucosal dissection (ESD) technique.

Minimum age:
18 years
Maximum age:
100 years
Participant sex, as recorded in the registry:
All sexes

This is an overview, not confirmation of eligibility. The study team reviews your records, the inclusion and exclusion criteria and the other protocol requirements.

Criteria published in the registry — English original

Inclusion Criteria: * epithelial pre-neoplastic (eg. adenoma, dysplasia) lesion on the esophageal, gastric, duodenal or colorectal mucosa * non-epithelial (eg. neuroendocrine tumor) lesion on the esophageal, gastric, duodenal or colorectal mucosa * age \> 18 years old * informed consent Exclusion Criteria: * age \< 18 years old * no informed consent

What taking part involves

The record does not specify how participants are assigned to groups.

Groups or procedures are not described in enough detail in the record. Ask the study team about participation.

Start of the whole study
1 January 2021
Completion of the whole study
January 2031 (estimated)

These are global study dates, not an individual's participation duration or an enrolment deadline.

Confirm participation duration, visit frequency and possible admissions with the centre team; they cannot be inferred from global study dates.

Ask the study team before travelling:

  • whether places are available at the chosen centre and how the first assessment is arranged
  • how often you need to attend the centre and whether a hospital stay is necessary
  • whether travel or accommodation costs are covered and under what conditions
  • which documents you need to prepare and whether a family member or carer can accompany you
Original registry title

Endoscopic Submucosal Dissection Registry

Updated in the registry: 12 November 2024

Data consulted: 19 November 2026

See the official record ↗

If the official record does not open, you can still read the information and contacts in this card. The ClinicalTrials.gov record is in English.

Source: ClinicalTrials.gov, the public registry of the US National Library of Medicine. Data retrieved on 19 Nov 2026.

Worth reading before you talk to your doctor

Material from our library to help you prepare your questions.

Where the official information lives

View the records in the official registries.

Where the data on this page comes from

The counts come from ClinicalTrials.gov and reflect trials marked in the registry as recruiting that also have at least one site in Romania marked as recruiting. We show cities, centre names and contacts when published. General contacts added from the OncoDots directory are labelled separately. A “recruiting” status does not guarantee that a site is still accepting patients on the day you check, because the registry may lag behind the situation at the hospital. For any decision, consult the official record and discuss it with your doctor.